⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DXCM News
DexCom, Inc.
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) Shareholders to Inquire about Securities Investigation
accessnewswire.com
DXCM
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Shareholders to Connect
accessnewswire.com
DXCM
DAV launches new resource page to support veterans with diabetes
prnewswire.com
DXCM
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DexCom, Inc. (DXCM) And Encourages Shareholders to Reach Out
accessnewswire.com
DXCM
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DexCom, Inc. (DXCM) and Encourages Shareholders to Learn More About the Investigation
accessnewswire.com
DXCM
Wearables in Pharma & Biotech Market worth $9.97 billion by 2031 | MarketsandMarkets™
prnewswire.com
BDX
ABT
MASI
AAPL
DXCM
MDT
IRTC
BIIB
GEHC
BSX
VIVK
Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
businesswire.com
DXCM
American Diversified Holdings Operating Division GlucoGuard Retains Global Contract Research Organization (CRO) to Begin Patient Studies as Required by the FDA Ready to Announce with Confidence?
newsfilecorp.com
DXCM
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) Stockholders to Inquire about Securities Investigation
accessnewswire.com
DXCM
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DexCom, Inc. (DXCM) and Encourages Investors to Learn More About the Investigation
accessnewswire.com
DXCM